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Purpose of the study
The majority of patients currently treated with cART live in
resource-limited settings and many patients are left on a
virologically failing regimen, typically an NNRTI-contain-
ing regimen. The aim was therefore to identify the level of
viremia at which CD4 counts significantly decrease in
patients on cART and the factors, including regimen type,
associated with CD4 count changes.
Methods
Annual CD4 slopes were calculated from three consecu-
tive CD4 measurements whilst the viral load was stable,
defined as <0.5 log10 copies/ml difference between the
highest and lowest viral loads measured at the same three
time-points. Generalised linear models, with adjustment
for repeated measurements within patients, were used to
model CD4 slopes.
Summary of results
A total of 7,231 patients were included in analyses con-
tributing 58,929 CD4 slopes. There was a median of six
slopes per patient included in analyses (IQR 3–12), and
the CD4 slope was calculated over a median time of 6.6
months (IQR 5.5–8.1 months). The median date of inclu-
sion into this study was May 2000 (IQR September
1998–May 2003) and median CD4 at this date was 354/
mm3 (IQR 220–529/mm3). Figure 1 illustrates the highly
significant differences in mean CD4 slope after stratifica-
tion by current viral load and current cART treatment sta-
tus. Patients on cART had more favourable (more positive
or less negative) mean CD4 slopes than those off cART for
any given level of viremia, whilst antiretroviral-naïve
patients had more favourable CD4 slopes than patients
who had previously started cART but were currently
undergoing a treatment interruption.
Among patients on cART, adjusting for relevant con-
founders, patients on a single PI-based cART regimen
(mean CD4 slope [SE] 43.3/mm3 [2.4]) or a ritonavir-
boosted PI (46.9/mm3 [2.3]) had more positive CD4
slopes compared to patients taking a non-nucleoside
reverse-transcriptase inhibitor (31.1/mm3 [1.7]) or a tri-
ple nucleoside regimen (30.2/mm3 [4.0], p < 0.0001).
Conclusion
The results from our study would suggest that some treat-
ment with cART is better than none, but also that better
CD4 count increases are obtained by using a PI or ritona-
vir-boosted PI-based regimen than by using an NNRTI-
based regimen. Patients were not randomised to treat-
ment and confounding by indication cannot be ruled out.
Patients with stable viremia unable to fully suppress HIV
replication should continue therapy and consideration
should be given to the use of a PI-based regimen.
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